Forest Laboratories Company Profile (NYSE:FRX)

About Forest Laboratories (NYSE:FRX)

Forest Laboratories logoForest Laboratories, Inc. (Forest), develops, manufactures and sells branded forms of ethical drug products, which requires a physician's prescription. The Company's products include Namenda, a N-methyl-D-aspartate (NMDA) antagonist for the treatment of moderate to severe dementia of the Alzheimer's type; Bystolic, a beta-blocker for the treatment of hypertension; Linzess, a guanylate cyclase type-C receptor agonist for the once-daily treatment for men and women suffering from IBS-C or CIC; Tudorza, a long-acting antimuscarinic agent for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and Viibryd, a SSRI and a 5-HT1A receptor partial agonist for the treatment of adults with depressive disorder (MDD). In February 2014, it acquired Aptalis. Effective July 2, 2014 Forest Laboratories Inc, a unit of Actavis PLC, acquired the entire share capital of Furiex Pharmaceuticals Inc.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:FRX
  • CUSIP: 34583810
  • Web: N/A
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0
  • Dividend Yield: 1.0%

Frequently Asked Questions for Forest Laboratories (NYSE:FRX)

What is Forest Laboratories' stock symbol?

Forest Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "FRX."

Who are some of Forest Laboratories' key competitors?

How do I buy Forest Laboratories stock?

Shares of Forest Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Forest Laboratories' stock price today?

One share of Forest Laboratories stock can currently be purchased for approximately $0.73.

MarketBeat Community Rating for Forest Laboratories (NYSE FRX)
Community Ranking:  2.2 out of 5 ( )
Outperform Votes:  165 (Vote Outperform)
Underperform Votes:  213 (Vote Underperform)
Total Votes:  378
MarketBeat's community ratings are surveys of what our community members think about Forest Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Forest Laboratories (NYSE:FRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Forest Laboratories (NYSE:FRX)
No equities research coverage for this company has been tracked by


Earnings History for Forest Laboratories (NYSE:FRX)
Earnings by Quarter for Forest Laboratories (NYSE:FRX)
Earnings History by Quarter for Forest Laboratories (NYSE FRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/29/2014Q414$0.45$0.87$959.00 million$1.05 millionViewN/AView Earnings Details
1/21/2014Q314$0.06$0.27$827.25 million$846.80 millionViewN/AView Earnings Details
7/23/2013Q1 2014$0.09$0.28$798.41 million$796.90 millionViewN/AView Earnings Details
4/23/2013Q4 2013$0.16$0.17$807.00 million$783.20 millionViewN/AView Earnings Details
1/15/2013Q3 2013($0.14)($0.21)$765.94 million$678.00 millionViewN/AView Earnings Details
10/16/2012$0.02$0.08ViewN/AView Earnings Details
7/17/2012$0.24$0.28ViewN/AView Earnings Details
4/17/2012$0.70$0.78ViewN/AView Earnings Details
1/17/2012$1.01$1.04ViewN/AView Earnings Details
10/18/2011$0.99$0.91ViewN/AView Earnings Details
7/19/2011$0.97$1.04ViewN/AView Earnings Details
4/19/2011$1.07$1.12ViewN/AView Earnings Details
1/18/2011$0.99$1.34ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Forest Laboratories (NYSE:FRX)
Current Year EPS Consensus Estimate: $-0.20 EPS


Dividend History for Forest Laboratories (NYSE:FRX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Forest Laboratories (NYSE:FRX)
Insider Trades by Quarter for Forest Laboratories (NYSE:FRX)
Insider Trades by Quarter for Forest Laboratories (NYSE:FRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/27/2014Howard SolomonDirectorSell250,000$65.41$16,352,500.00View SEC Filing  
1/23/2014Howard SolomonDirectorSell250,000$67.13$16,782,500.00View SEC Filing  
1/22/2014Jerome LynchSVPSell135,625$67.28$9,124,850.00View SEC Filing  
8/26/2013Lawrence OlanoffDirectorSell1,104$42.96$47,427.84View SEC Filing  
8/21/2013Perier Francis, Jr.CFOSell12,000$43.00$516,000.00View SEC Filing  
9/4/2012Carl C IcahnMajor ShareholderBuy86,848$34.64$3,008,414.72View SEC Filing  
8/29/2012Carl C IcahnMajor ShareholderBuy331,406$34.65$11,483,217.90View SEC Filing  
8/24/2012Carl C IcahnMajor ShareholderBuy1,343,837$34.57$46,456,445.09View SEC Filing  
8/21/2012Carl C IcahnMajor ShareholderBuy1,962,011$34.18$67,061,535.98View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Forest Laboratories (NYSE:FRX)
Latest Headlines for Forest Laboratories (NYSE:FRX)



Forest Laboratories (FRX) Chart for Thursday, July, 20, 2017

This page was last updated on 7/20/2017 by Staff